Departments & Organizations
I am a clinician-scientist with an interest in the matricellular proteins, PEDF and TSP-1, which are best known as inhibitors of angiogenesis. The recent identification of the PEDF null state as the cause of Osteogenesis Imperfecta (OI) Type VI has illuminated its biology. Specifically, the phenotypes associated with high PEDF conditions (metabolic syndrome, adiposity) and null PEDF states (OI Type VI) indicate that PEDF functions to regulate mesenchymal stem cell (MSC) lineage specification. Based on these clinical insights, we have demonstrated that PEDF can direct MSC fate. This is significant because previous unbiased proteomic screens have postulated PEDF's role in stem cell pluripotency. This rare single gene null state has allowed us to interrogate PEDF's role in other more common disease conditions.
Education & Training
|MD||Medical College of Pennsylvania (1998)|
|BA||Wesleyan University (1989)|
|Research Fellow||Northwestern University School of Medicine|
|Clinical Fellow||Northwestern University School of Medicine|
|Intern||Northwestern University School of Medicine|